rheumatology centres in Khartoum between December 2008 and September 2010 were included. Samples analysed in Uppsala for anti-CCP and IgM RF.

Results The mean age at inclusion was 48 years (range 14–80). Median disease duration was 3.8 years. ESR data was available for 113 patients, with a mean of 60.3 mm/1 h (range 10–140). Mean blood haemoglobin was 12.1 g/L. On clinical examination, 26% (68/264) had Z deformity, 14% (38/264) had Swan neck deformity and 9% (25/264) had Boutonniere deformity. X-rays of hands were available for 86 patients, with 49/86 (57%) showing erosions. 40% were treated with methotrexate, 7% with sulfasalazine 3% azathioprine, 2% with leflunomide and 2% with hydroxychloroquine in monotherapy. 41% (16%) were treated with steroids + DMARD monotherapy, 48% (18%) with DMARD combinations. Three % were treated with steroids only, and 9% with NSAIDs only.

52% were anti-CCP2 positive and 51% were IgM RF positive, corresponding to 97.6% specificity compared to the Sudanese healthy controls. Compared to Swedish RA patients (Rönnefeld et al., ARD 2012) Sudanese patients had 270% higher mean ESR (55 versus 21 mm/h; p < 0.0001), and significantly lower age of disease onset (median 43 versus 56 years, p < 0.0001).

Conclusions RA as presented in an outpatient clinic in Khartoum is severe and with earlier RA onset than in Sweden. Sudanese patients show significantly higher ESR levels than Swedish patients, more Sudanese than Nigerian RA patients have radiological erosions, and the number of patients with classical hand deformities is substantial. Blood haemoglobin levels are rather well preserved. Immunological and genetic characterisation is now underway.

CONCLUSIONS

A6.11 INTRA-ARTICULAR OVEREXPRESSION OF INTERLEUKIN-10 DIMINISHES CARTILAGE PROTEOGLYCAN DEPLETION IN STREPTOCOCCAL CELL WALL ARTHRITIS: A PROMISING CONCEPT FOR DISEASE-REGULATED GENE THERAPY
doi:10.1136/annrheumdis-2013-203220.11
Eline A Vermeij, Mathijs GA Broeren, Miranda B Bennink, Onno J Arntz, Wim B van den Berg, Fons AJ van de Loo. Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre

Background and Objectives Local gene therapy for arthritis, with the use of disease-inducible promoters, represents a promising alternative for coping with side effects of the conventional treatments. These disease-inducible promoters react to transcription factors that are released during inflammation and therefore only produce a therapeutic protein when necessary. Interleukin-10 (IL-10) could play an important regulatory role in streptococcal cell wall arthritis (SCW), and therapeutic effects are present when IL-10 was injected systemically (Lubberts et al., 1998).

In this study IL-10 was used to investigate the potential of intra-articular gene therapy in an acute model of arthritis.

Materials and Methods C57Bl6/N mice were injected intra-articularly in the kneejoint with lentivirus, expressing the therapeutic protein IL-10 or the luciferase reporter. Inducible promoters S100a8, Cxcl1, MMP13, Saa3, IL-1b, and TNFap6, which were selected from endogenous genes differentially regulated in the inflamed synovium of collagen-induced arthritis mice, were used to express luciferase. The constitutive PKG promoter was used to express IL-10. Arthritis was induced by injection of 25 μg SCW into the knee joint cavity 4 days later. At 1, 4, and 7 days after arthritis induction, mice treated with PKG-IL10 were sacrificed, and knee joints were dissected for either histological analysis, or RNA isolation for qPCR analysis. At the same timepoints, in-vivo bioluminescent imaging was performed in mice treated with the inducible promoter reporter, using the IVIS Lumina system.

Results PKG-IL10 significantly decreased proteoglycan (PG) depletion at day 4 and 7 after arthritis induction, probably by inhibiting MMPs and upregulating TIMPs. No effects on inflammation were seen histologically, but synovial IL-1, IL-6 and TNFa gene expressions were markedly decreased at day 1. The inducible promoters all showed a different activation profile during the course of inflammation, meaning they all react differently during the disease process. The Saa3 promoter showed the highest upregulation (120 fold) and was the only promoter which showed an early peak in activation at day 1 after arthritis induction, resembling neutrophil influx.

Conclusions Effects of IL-10 were seen on PG depletion and gene expressions, therefore IL-10 can be a feasible therapeutic protein to modulate SCW arthritis. On the other hand, the Saa3 promoter seems to be the best candidate for local intra-articular gene therapy with the use of disease-inducible promoters, because it showed a high and quick upregulation during disease activity. Hence, combining the Saa3 promoter with the therapeutic protein IL-10, can be a promising combination to modulate an acute model of arthritis using disease regulated gene therapy.

A6.12 LATERAL EPICONDYLE TENDON LESIONS TREATMENT WITH PLATELET GROWTH FACTORS
P González-Moreno, R Santos Sanabria, R Hernández-Sánchez, JL Marenco. Valme University Hospital, Seville, Spain

Background Chronic painful tendon disorders are common and difficult to treat. Recently, research has focused on regenerative therapies based in the injections with autologous platelet growth factors (PGRF). Two randomised clinical trials involving patients with tendinopathy receiving autologous PGRF showed conflicting results. However, better outcomes were observed among individuals randomised to PGRF injections in the trial randomising patients with lateral epicondyle tendon lesions. The potential benefit of PGRF injections in patients without response to standard therapy is not established.

Objectives To evaluate the efficacy and safety of local injections with autologous PGRF to treat epicondylitis in patients refractory to standard therapy.

Methods Patients with epicondylitis who had received standard therapy including corticosteroid local injections and NSAIDS, with or without local ice or orthosis, were included in this prospective study. Patients being treated with physiotherapy were excluded. Patients were treated with one PGRF injection per month during three months. Symptoms, side effects of injections, visual analogic scale (VAS) were recorded in every visit. Fried man test was applied to compare VAS among visits.

Results 17 patients were included, 12 (57%) of whom were men. The median age was 52 (range: 42–61) years. 8 individuals have completed the scheduled therapy, 17 have reached 1 month. Median (RIQ) VAS were: at baseline 7 (6–9); at 1 month 6 (4–8); at 2 months 5 (3–9.5) (p < 0.001). An improvement in VAS was observed in 14 (82%) patients at 1 month, and 6 (75%) at 2 month. No significant side effects were observed.

Conclusions Local PGRF injections were efficacious to treat lateral epicondyle tendon lesions in patients without response to previous standard therapy. Local PGRF injections were well-tolerated.

A6.13 MINOR DISCREPANCY BETWEEN BMD OF SPINE AND HIP
Poran Farahifard, Shahid Sadoughi, Mohammad Bagher Owlia, Shahid Sadoughi. University of Medical Sciences, Yazd, Iran

Background and Objectives Diagnostic discordance for osteoporosis is the observation that the T-score of an individual patient varies from one key measurement site to another, falling into two different diagnostic categories of minor and major discordances, identified by the World Health Organization (WHO) classification